Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, Bianchini G, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V. Miglietta F, et al. Among authors: del mastro l. Cancer Treat Rev. 2023 Mar;114:102511. doi: 10.1016/j.ctrv.2023.102511. Epub 2023 Jan 6. Cancer Treat Rev. 2023. PMID: 36638600 Free article. Review.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
Gampenrieder SP, Dezentjé V, Lambertini M, de Nonneville A, Marhold M, Le Du F, Cortés Salgado A, Alpuim Costa D, Vaz Batista M, Chic Ruché N, Tinchon C, Petzer A, Blondeaux E, Del Mastro L, Targato G, Bertucci F, Gonçalves A, Viret F, Bartsch R, Mannsbart C, Deleuze A, Robert L, Saavedra Serrano C, Gion Cortés M, Sampaio-Alves M, Vitorino M, Pecen L, Singer C, Harbeck N, Rinnerthaler G, Greil R; AGMT Study Group. Gampenrieder SP, et al. Among authors: del mastro l. ESMO Open. 2023 Feb;8(1):100747. doi: 10.1016/j.esmoop.2022.100747. Epub 2022 Dec 21. ESMO Open. 2023. PMID: 36563519 Free PMC article.
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.
D'Arienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M, Caputo R, Puglisi F, Giuliano M, Del Mastro L, Arpino G, De Laurentiis M, Montemurro F. D'Arienzo A, et al. Among authors: del mastro l. EClinicalMedicine. 2023 Jul 27;62:102113. doi: 10.1016/j.eclinm.2023.102113. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37554126 Free PMC article. Review.
News from the San Antonio Breast Cancer Symposium 2022.
Gennari A, Curigliano G, Del Mastro L, Guarneri V, Puglisi F, Zambelli A. Gennari A, et al. Among authors: del mastro l. Breast Care (Basel). 2023 Jun;18(3):223-227. doi: 10.1159/000530183. Epub 2023 Mar 16. Breast Care (Basel). 2023. PMID: 37928813 No abstract available.
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients.
Arenare L, Porta C, Barberio D, Terzolo S, Zagonel V, Pisconti S, Del Mastro L, Pinto C, Bilancia D, Cinieri S, Rizzo M, Migliaccio G, Montesarchio V, Del Campo L, De Lorenzo F, Iannelli E, Traclò F, Gitto L, Vaccaro MC, Frontini L, Giannarelli D, Bryce J, Piccirillo MC, Jommi C, Efficace F, Riva S, Di Maio M, Gallo C, Perrone F. Arenare L, et al. Among authors: del campo l, del mastro l. ESMO Open. 2023 Dec;8(6):102192. doi: 10.1016/j.esmoop.2023.102192. Epub 2023 Dec 5. ESMO Open. 2023. PMID: 38052104 Free PMC article.
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Loibl S, et al. Among authors: del mastro l. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. Ann Oncol. 2024. PMID: 38101773 No abstract available.
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: del mastro l. Cancer Treat Rev. 2024 Feb;123:102672. doi: 10.1016/j.ctrv.2023.102672. Epub 2023 Dec 14. Cancer Treat Rev. 2024. PMID: 38118302 Free article. Review.
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Kaidar-Person O, et al. Among authors: del mastro l. Radiother Oncol. 2023 Dec 19:110060. doi: 10.1016/j.radonc.2023.110060. Online ahead of print. Radiother Oncol. 2023. PMID: 38122852 Free article. Review.
325 results